These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 27709305)
1. Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US: insights into the construction of a sophisticated premarketing evaluation. Saito M; Iwasaki K J Artif Organs; 2017 Mar; 20(1):62-70. PubMed ID: 27709305 [TBL] [Abstract][Full Text] [Related]
2. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences. Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575 [TBL] [Abstract][Full Text] [Related]
3. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. Varma T; Wallach JD; Miller JE; Schnabel D; Skydel JJ; Zhang AD; Dinan MA; Ross JS; Gross CP JAMA Netw Open; 2021 Apr; 4(4):e217063. PubMed ID: 33877309 [TBL] [Abstract][Full Text] [Related]
4. Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval. Matsushita S; Tachibana K; Kusakabe T; Hirayama R; Tsutsumi Y; Kondoh M Clin Transl Sci; 2021 May; 14(3):806-811. PubMed ID: 33048440 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of drug postmarketing all-case surveillance as a safety measure in Japan. Kondo H; Masamune K Ther Adv Drug Saf; 2021; 12():20420986211065215. PubMed ID: 34987750 [TBL] [Abstract][Full Text] [Related]
6. Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications. Haque A; Daniel S; Maxwell T; Boerstoel M Clin Ther; 2017 Apr; 39(4):675-685. PubMed ID: 28392076 [TBL] [Abstract][Full Text] [Related]
7. Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis. Iijima K; Umezu M; Iwasaki K PLoS One; 2016; 11(6):e0153662. PubMed ID: 27248140 [TBL] [Abstract][Full Text] [Related]
8. Postmarketing evaluations help determine contraceptive safety, efficacy. Netw Res Triangle Park N C; 1988; 9(2):1-2, 7. PubMed ID: 12280950 [TBL] [Abstract][Full Text] [Related]
9. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. Moore TJ; Furberg CD JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236 [TBL] [Abstract][Full Text] [Related]
10. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457 [TBL] [Abstract][Full Text] [Related]
11. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns. Goldman SA Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417 [TBL] [Abstract][Full Text] [Related]
12. The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Llanos L; Moreu R; Ortin T; Peiró AM; Pascual S; Bellot P; Barquero C; Francés R; Such J; Pérez-Mateo M; Horga JF; Zapater P Aliment Pharmacol Ther; 2010 Jun; 31(12):1337-45. PubMed ID: 20331578 [TBL] [Abstract][Full Text] [Related]
13. Postmarketing safety of biologics and biological devices. Woo EJ Spine J; 2014 Mar; 14(3):560-5. PubMed ID: 24342704 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Curtis JR; Perez-Gutthann S; Suissa S; Napalkov P; Singh N; Thompson L; Porter-Brown B; Semin Arthritis Rheum; 2015 Feb; 44(4):381-8. PubMed ID: 25300699 [TBL] [Abstract][Full Text] [Related]
15. New Regulatory Framework for Medical Devices in Japan: Current Regulatory Considerations Regarding Clinical Studies. Konishi A; Isobe S; Sato D J Vasc Interv Radiol; 2018 May; 29(5):657-660. PubMed ID: 29548874 [TBL] [Abstract][Full Text] [Related]
16. [Evaluation of new implantable medical devices]. Loisance D Bull Acad Natl Med; 2012 Jan; 196(1):175-92. PubMed ID: 23259342 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. Rathi VK; Krumholz HM; Masoudi FA; Ross JS JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798 [TBL] [Abstract][Full Text] [Related]
18. Postmarketing safety reports for human drug and biological products; electronic submission requirements. Final rule. Food and Drug Administration, HHS Fed Regist; 2014 Jun; 79(111):33072-92. PubMed ID: 24922981 [TBL] [Abstract][Full Text] [Related]
19. Cochlear implants: overview of safety and effectiveness. The FDA evaluation. Yin L; Segerson DA Otolaryngol Clin North Am; 1986 May; 19(2):423-33. PubMed ID: 3520445 [TBL] [Abstract][Full Text] [Related]
20. The role of databases in drug postmarketing surveillance. Rodriguez EM; Staffa JA; Graham DJ Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]